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We investigated the antifungal activity of novel a 2-bromo-2-chloro-
2-(4-chlorophenylsulfonyl)-1-phenylethanone (compound 4). The synthesis of compound
4 was commenced from sodium 4-chlorobenzene sulfinate and the final product was
obtained by treatment of α-chloro-β-keto-sulfone with sodium hypobromite. The
sensitivity of 63 clinical isolates belonging to the most relevant Candida species toward
compound 4 using the method M27-A3 was evaluated. We observed among most of the
clinical strains of C. albicans MIC ranging from 0.00195 to 0.0078µg/mL. Compound
4 at 32µg/mL exhibited fungicidal activity against nine Candida strains tested using
the MFC assay. Compound 4 displayed anti-Candida activity (with clear endpoint)
against 22% of clinical strains of Candida. Under compound 4, Candida susceptibility
and tolerance, namely paradoxical effect (PG), was found for only two clinical isolates
(C. glabrata and C. parapsilosis) and reference strain 14053 using both M27-A3 and
MFC method. We found that compound 4 does not induce toxicity in vivo against larvae
of Galleria mellonella (≥97% survival) and it displays reduced toxicity on mammalian cells
in vitro (<CC20 at 64µg/mL). Furthermore, XTT assay denoted clear metabolic activity
of sessile cells in the presence of compound 4. Thus, the effect of compound 4 on
formed C. albicans biofilms was minimal. Moreover, strain 90028 exhibited no defects in
hyphal growth on Caco-2 monolayer under compound 4 influence at MIC = 16µg/mL.
The MIC values of compound 4 against C. albicans 90028, in medium with sorbitol did
not suggest that compound 4 acts by inhibiting fungal cell wall synthesis. Our findings
with compound 4 suggest a general strategy for antifungal agent development that
might be useful in limiting the emergence of resistance in Candida strains.
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INTRODUCTION
Members of the Candida genus are the third most common cause of hospital-acquired systemic
infections, which are associated to high mortality rates worldwide (Falagas et al., 2010). Five
major classes of antifungal drugs (fluoropyrimidine analogs, polyenes, azoles, allylamines, and
echinocandins) are currently available and target different metabolic pathways, namely cell wall
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synthesis, pyrimidine salvage, or act by binding to ergosterol
and cause osmotic leakage. Although they are effective in
the treatment of candidiasis, the main disadvantages of these
antimycotics, are the high toxicity to host tissues, emergence
of drug-resistant strains, and high costs (Rajeshkumar and
Sundararaman, 2012). In light of this, it has become essential to
develop new drugs designed to circumvent resistance or target
alternative cellular processes. Our early reports on the antifungal
potential of the newly synthesized halogenated methyl sulfones
(Staniszewska et al., 2015a,b) has spurred significant interest in
the synthesis of new α-chloro β-keto-based sulfone which may
offer improved antifungal activity.
It has been reported that paradoxical growth could increase
the probability of the appearance of stable resistance among
fungal strains and treatment failure (Rueda et al., 2014).
This phenomenon was described mainly to echinocandins and
fluconazole at high concentrations (Chamilos et al., 2007;
Zanette and Kontoyiannis, 2013). As its mechanisms are
incompletely understood, further studies on the mechanism of
the newly synthesized agents paradoxical effect in regard to
different Candida species emerged from studies of other authors
(Chamilos et al., 2007; Zanette and Kontoyiannis, 2013; Juvvadi
et al., 2015).
The ability of C. albicans to form biofilms is a major virulence
attribute and a challenge to be managed (Maiolo et al., 2014;
Gulati and Nobile, 2016). The effect of biofilm formation on
pathogenicity and their inherent resistance to the majority of
known antifungals emphasize the need for the development
of new antifungals with efficiency against the biofilm mode of
growth (Gulati and Nobile, 2016; Martins et al., 2016; Rajendran
et al., 2016). Furthermore, biofilm formation has been reported as
an independent predictor of mortality, in addition to inadequate
antifungal therapy (Rajendran et al., 2016). Candida albicans is
polymorphic fungus with the ability to form yeast and hyphal
cells, both critical for biofilm development and maintenance
(Gulati and Nobile, 2016). Our recent studies (Bondaryk et al.,
2015; Staniszewska et al., 2015a,b) demonstrated that inhibition
of hyphal growth attenuated virulence in an in vitro model
of superficial candidiasis, and a disruption of this cellular
process might serve as an effective therapeutic intervention.
Thus, inhibition of dimorphism may provide an alternative
approach allowing finding compounds with the potential to
control C. albicans infections (Lu et al., 2014). Hyphae are
required for stable biofilm formation, which suggests that this cell
type has a unique role in this process (Finkel and Mitchell, 2011).
Here we identify and characterize the novel β-ketosulfone
derivative 2-bromo-2-chloro-2-(4-chlorophenylsulfonyl)-1-
phenylethanone, the first to our knowledge active against
C. albicans wild-type reference strains and a large number of
clinical isolates. We sought to determine whether clinical isolates
are able to grow at β-ketosulfone concentrations higher than
the MIC, which is termed the Paradoxical Growth effect (PG).
β-ketosulfone was tested for its ability to destroy pre-formed
C. albicans biofilm. We investigated β-ketosulfone mechanism
of action, including the effects of the compound on the cell
wall, cell morphology, and viability, as well as the yeast-to-
hyphal form transition. We estimated the cytotoxic effect of
β-ketosulfone against mammalian cells in vitro and Galleria
mellonella in vivo.
MATERIALS AND METHODS
Synthesis of 2-Bromo-2-Chloro-2-(4-
Chlorophenylsulfonyl)-1-Phenylethanone
(Compound 4)
The synthesis of 2-bromo-2-chloro-2-(4-chlorophenylsulfonyl)-
1-phenylethanone (compound 4, Figure 1) was commenced
from sodium 4-chlorobenzene sulfinate. The final product was
obtained by treatment of α-chloro-β-keto-sulfone with sodium
hypobromite (Staniszewska et al., 2014 Polish Patent Application
PL-P.408765). Detail procedures and characteristic data of
synthesized compounds are given below.
Synthesis of 2-(4-Chlorophenylsulfonyl)-1-
Phenylethanone (2)
All reactions were set up in the air and using undistilled solvents.
The reagents were purchased from commercial sources and
were used without further purification. The reported yields refer
to pure isolated products. Reactions were monitored by gas
chromatography (GC) and/or thin layer chromatography (TLC)
carried out on silica gel plates, using UV light. 1H NMR spectra
were recorded on a Varian Mercury 400MHz spectrometer in
CDCl3, using TMS (tetramethylsilane) as an internal standard;
all signals are reported in ppm as (s = singlet, m = multiplet,
integration). Mass spectra were recorded with a Micro-mass
ESI Q-TOF spectrometer. All melting points (m.p.) are given
uncorrected.
Compound (2) was synthesized according to the procedure
described in publication (Suryakiran et al., 2006). A mixture of
the sodium 4-chlorobenzene sulfinate (2.2 g, 11mmol) and the 2-
bromo-1-phenylethanone (2 g, 10mmol) was taken in 50mL of
polyethylene glycol (PEG 400), and stirred at room temperature
for 2 h. After completion of the reaction, as monitored by TLC,
the reaction mass was poured into water (100mL) and extracted
into ethyl acetate (3 • 20mL). The organic layer was removed
under reduced pressure, and the crude product was purified by
crystallization from ethanol. Yield 86%, m.p. 134–135 oC.1H
NMR (400MHz, CDCl3) δ 4.53 (s, 2H), 7.58–7.93 (m, 9H). 13C
NMR (100 MHz, CDCl3) δ 171.96, 141.47, 137.8, 136.31, 135.62,
132.97, 129.84, 129.65, 127.71, 64.65.
FIGURE 1 | Chemical structure of β-ketosulfone (compound 4).
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2-Chloro-2-(4-Chlorophenylsulfonyl)-1-
Phenylethanone (3)
Compound (3) was synthesized in analogy to the procedure
described in the paper (Suryakiran et al., 2007). To the solution of
2-(4-chlorophenylsulfonyl)-1-phenylethanone (2.95 g, 10mmol)
in acetic acid (10mL) was added KCl (0.82 g 11mmol) and
30% hydrogen peroxide (80mmol). The reaction was stirred at
room temperature for 10 h. After completion of the reaction, as
monitored by TLC, the acetic acid was removed under reduced
pressure, water (10mL) was added and the product extracted
into ethyl acetate (3 • 20mL). The combined organic extracts
were dried over anhydrous sodium sulfate and evaporated under
reduced pressure to give the crude product, which was purified
on a silica gel column using hexane: ethyl acetate (9:2) as eluent.
Yield 76%, m.p. 145.5–146.5◦C. 1H NMR (400MHz, CDCl3) δ
6.24 (s, 1H), 7.65–8.64 (m, 9H). 13C NMR (100MHz, CDCl3)
δ 171.96, 144.77, 137.4, 135.88, 133.76, 132.36, 130.91, 130.48,
128.23, 69.35.
2-Bromo-2-Chloro-2-(4-Chlorophenyl
sulfonyl)-1-Phenylethanone (4)
2-Chloro-2-(4-chlorophenylsulfonyl)-1-phenylethanone (3)
(3.19 g, 10mmol) was added to freshly prepared 14% w/w aq
sodium hypobromite (80mL), and the resulting mixture was
stirred at 75◦C for 4 h. After cooling the mixture to ambient
temperature, the precipitate was filtered off, washed with water,
dried, and recrystallized from 2-propanol. Product (4) was
obtained in 86% yield (3.55 g, 8.70mmol); mp 165–166◦C. 1H
NMR (400MHz, CDCl3) δ 7.63–8.52 (m, 9H).). 13C NMR (100
MHz, CDCl3) δ 172.93, 146.27, 137.38, 136.71, 135.62, 132.48,
130.95, 129.84, 129.65, 69.52. HRMS (ESI+, m/z): [M+H]+,
found 406.8874. C14H9BrCl2O3S, requires 406.8905.
Strains, Media, and Growth Conditions
The wild type reference strains and the clinical isolates used in
the study are listed in Table 1. The clinical isolates were acquired
from Maria Skłodowska—Curie Oncology Centre, Hospital of
Warsaw Medical University and Hospital of Infectious Diseases
in Warsaw, and used throughout the study. Candida isolates
obtained from both sterile and non-sterile sites were collected
from 2012 to 2014. The isolates were identified based on colony
color on CHROMagar Candidamedium and evaluated following
API 20C AUX carbohydrate assimilation patterns (Madhavan
et al., 2011). Strains were stored on ceramic beads in aMicrobank
tube (Prolab Diagnostics, Canada) at −70◦C. Prior to the
respective examinations, routine cultures were conducted at
30◦C for 18 h in Yeast extract-peptone-dextrose medium (YEPD;
Staniszewska et al., 2015b). The study was approved by the Ethics
Committee of the National Institute of Public Health-National
Institute of Hygiene (Opinion 5/2012, 28.06.2012 and Appendix
18.04.2013) and all patients signed an informed consent form.
Antifungal Susceptibility Testing and
Evaluation of Interaction with Compound 4
Antifungal susceptibility to compound 4 was determined for
each strain using the Method M27-A3, CISI, 2008. The final
TABLE 1 | Strains used in current study.
Organism Strain designation
and sample number
Origin
Candida albicans (C.a.) 90028 ATCC Reference
14053 ATCC Reference
28836 ATCC Reference
C.a. 82 Blood sample
C.a. 129 Blood sample
C.a. 171 Blood sample
C.a. 87 Drain swab
C.a. 96 Nose swab
C.a. 97 Nose swab
C.a. 128 Sputum sample
C.a. 131 Stool sample
C.a. 15 Vaginal swab
C.a. 16 Vaginal swab
C.a. 18 Vaginal swab
C.a. 28 Vaginal swab
C.a. 5 Wound swab
C.a. 86 Wound swab
C.a. 89 Wound swab
Candida dubliniensis
(C.d.)
MYA-581 ATCC Reference
Candida glabrata (C.g.) C.g. 118 Anus swab
C.g. 144 Aspirate sample
C.g. 44 Blood sample
C.g. 4 Drain swab
C.g. 40 Drain swab
C.g. 70 Drain swab
C.g. 85 Drain swab
C.g. 88 Drain swab
C.g. 92 Drain swab
C.g. 99 Drain swab
C.g. 67 Nose swab
C.g. 69 Nose swab
C.g. 117 Oral cavity swab
C.g. 41 Stoma swab
C.g. 73 Wound swab
C.g. 74 Wound swab
C.g. 75 Wound swab
Candida kefyr (C.k.) C.k. 27 Vaginal swab
C. krusei (C.kr.) 6258 ATCC Reference
C.kr. 122 Aspirate sample
C.kr. 119 Bile sample
C.kr. 48 Blood sample
C.kr. 39 Drain swab
Candida parapsilosis
(C.p.)
22019 ATCC Reference
C.p. 45 Blood sample
C. p. 47 Blood sample
C.p. 54 Blood sample
(Continued)
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TABLE 1 | Continued
Organism Strain designation
and sample number
Origin
C.p. 56 Blood sample
C.p. 98 Blood sample
C.p. 43 Blood sample
from central
venous catheter
C.p. 46 Central venous
catheter swab
C.p. 55 Central venous
catheter swab
C.p. 71 Drain swab
C.p. 166 Oral cavity swab
C.p. 120 Ulcer swab
Candida tropicalis (C.t.) C.t. 53 Blood sample
C.t. 6 Central venous
catheter swab
C.t. 1 Cerberospinal
fluid
C.t. 68 Drain swab
C.t. 72 Drain swab
C.t. 150 Sputum sample
C.t. 152 Tongue swab
C.t. 168 Urine sample
C.t. 80 Wound swab
inoculum, ranging from 0.5 × 102 to 2.5 × 103 cfu/mL was
prepared in synthetic RPMI 1640 medium (Gibco R©, UK). The
compound test wells (PTW) were prepared with stock solution
of compound 4 (1600µg/mL) dissolved in water 66% DMSO.
Subsequently, serial two-fold dilutions were performed with
RPMI 1640 medium. Then, the yeast cells suspension and
compound 4 (final dilution 1:100) were dispensed at final volume
of 250µL/well into 96-well microplates. The compound 4 was
tested at concentrations that ranged from 0.00195 to 32µg/mL.
As control, DMSO was tested at concentration of 0.66% (v/v)
in antifungal susceptibility testing. At this concentration, DMSO
was not able to inhibit the fungal growth. Growth control
wells (GCW; containing medium, inoculum, the same amount
of DMSO used in PTW, but compound-free) and sterility
control wells (SCW; sample, medium, and sterile water replacing
inoculum) were included for each strain tested. Microplates, after
18 and 48-h incubation at 35◦C, were read with the Spark Control
M10 (Tecan Group Ltd., Austria). Percentage of cell inhibition
was read spectrophotometrically (optical density OD405) and
the endpoint was calculated as a 100% reduction in OD405 as
compared to the growth in control wells. Growth reduction
for each compound concentration was calculated as follows: %
of inhibition = 100 − (OD405 PTW − OD405 SCW)/(OD405
GCW − OD405 SCW). Additionally, the range of Amphotericin
B (Sigma-Aldrich, USA) concentrations tested was 0.0195–
2.5µg/mL against C. albicans 90028. These concentrations were
diluted in RPMI and were subsequently used in the assay as
the reference concentrations. Minimal inhibitory concentrations
(MICs) of compound were read visually after 18 and 48 h after
shaking incubation at 35◦C. We used two endpoint criteria
for MIC determination: (i) total inhibition (MICTI), the lowest
concentration of compound that yielded no visible growth
(a clear well); and (ii) partial inhibition (MICPI), the lowest
concentration that produced a prominent decrease in turbidity
compared to that of the drug–free control (visual assessment;
Majoros et al., 2005). For determination of theminimal fungicidal
concentration (MFC), we used the method described by Majoros
et al. (2005). The MFC was defined as the lowest compound
concentration that killed ≥99.9% of viable cells, compared with
the starting inoculum (≥3-log reduction). Tests were performed
in triplicate with randomly selected strains at the range of
concentrations of compound 4 from 2 to 32µg/mL. Briefly,
50-µL aliquots from the selected wells of plates were removed
after 48 h of incubation at 35◦C. Then after 1/10,000 dilutions,
100µL aliquots were placed onto agent-free Sabouraud dextrose
agar plates and incubated at 35◦C for 48 h (Rueda et al.,
2014). Paradoxical growth (PG), the reduced fungicidal effect
at higher concentrations, was also evaluated in MFC assay. In
this assay, Paradoxical growth was defined as killing activity
(99.9% reduction of the starting inoculum) observed at =2 drug
dilutions above MIC, but consistent lack of killing by higher
concentrations (Shields et al., 2011).
Sorbitol Assay—Effect of Compound 4 on
the Cell Wall of C. albicans
The MIC of compound 4 was determined in the presence of
an osmotic protector using the Method M27-A3, CISI, 2008.
SDB medium was added to each well of the microplate and
serial dilutions of compound 4 (2.08–1066µg/mL) were carried.
Finally, 100µL of inoculum (0.5 × 102–2.5 × 103 cfu/mL)
prepared in SDB medium supplemented with sorbitol at final
concentration of 0.8M (Sigma-Aldrich) was transferred to wells
as described Pereira et al. (2016). Plates were incubated at 35◦C
and read after 2 and 7 days (Lima et al., 2013; Freires et al., 2014;
Pereira et al., 2016).
Cytotoxicity assays in vitro
Vero cells (ATCC CCL-81, LGC Poland) were cultured in
EMEM medium (10% FCS, 1mM pyruvic acid, 100 U/mL
penicillin and 0,1 mg/mL streptomycin, LGC Poland) at 37◦C
in a humidified atmosphere containing 5% CO2. Vero cells were
seeded into a 96-well plate (2 × 104 cells per well). After an
overnight incubation at 37◦C in 5% CO2, compound 4 was
added to cells, respectively. A dilution series of compound 4
(256–0.125µg/mL final concentrations) were then supplied to
wells so that each well contained 200µl of medium in total. The
plate was then incubated at 37◦C in a humidified atmosphere
5% CO2 for 18 h, and then the toxic effects of the extracts were
assayed using the XTT (sodium 3′-[1-(phenyl amino-carbonyl)-
3,4-tetrazolium]-bis-[4-methoxy-6-nitrobenzene sulfonic acid
hydrate) cytotoxicity assay according to the manufacturer (Roche
Diagnostics GmbH, Germany). Fifty micro-liters of XTT reagent
was added to each well and incubated for 18 h. For comparison,
DMSO was used at the proper concentration (see above). The
concentration at which the cell viability had dropped by 50% was
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recorded as the cytotoxic concentration (CC50; Cavalcanti et al.,
2012). The optical densities of wells were measured at 450 nm
(690 nm reference wavelength) using BIOTEK ELX800multi well
reader.
In vivo Cytotoxicity Testing of Compound 4
Galleria mellonella (Lepidoptera: Pyralidae) caterpillars in the
final instar larval stage were used in the study (Insua et al., 2013;
Li et al., 2013). A Hamilton syringe with a 30-gage needle was
used to deliver compound 4 at concentrations ranging from 32 to
0.25µg/mL in volume of 10µL into the haemocoel of each larva
via the last pro-leg. Before injection, the area was cleaned using
an alcohol swab. Ten randomly chosen caterpillars (231± 40mg)
were injected at each concentration of compound 4.Two controls
were employed in all assays: the first one consisted of larvae which
were untouched, the second control contained larvae whose pro-
leg was inoculated with DMSO to ensure that death was not due
to solvent. Larvae were placed into Petri dishes and incubated in
dark at 37◦C in a stationary incubator (Mowlds and Kavanagh,
2008). The number of dead larvae was scored daily for up to 72 h
after injection. Larval death was assessed by the lack ofmovement
of larvae in response to physical stimuli with melanisation of the
cuticle. Results represent the mean percentage survival of larvae
following the combination of the data from all experiments.
Confocal Microscopy
The assessment of compound 4 influence on C. albicans
morphogenesis during 18-h growth on Caco-2 monolayer was
performed by using Fluoview FV10i Microscope (Olympus,
USA). Briefly, Caco-2 cells grown on 12mm glass slides (Thermo
SCIENTIFIC, Germany) in 24-well plates were inoculated after
21-day post-seeding with 1–1.2 × 106 log phase yeast cells/mL
of the C. albicans 90028 strain. After 18-h incubation at 37◦C
in EMEM medium (10% FCS, 1mM pyruvic acid, without
antibiotics, or antifungal agents), C. albicans sessile cells were
treated with compound 4 at 16µg/mL for 18 h. Amphotericin B
at concentration of 1µg/mL was used as a control. Then, slides
were gently removed and washed three times with PBS to remove
non-adherent C. albicans cells, and samples were stained with
Propidium Iodide (PI, Roche Diagnostics GmbH), according to
manufacturer’s instruction. Untreated control cells were stained
with Acridine Orange to show Caco-2 monolayer. Experiments
were performed in duplicate and repeated at least three times.
Antifungal Activity of Compound 4 against
Candida albicans Biofilms
Biofilms were formed 96-well plates as previously described
(Pierce et al., 2010). After biofilm formation, the medium was
discarded and non-adherent cells were removed by washing
the biofilms three times with PBS. The highest working
concentration of compound 4 (256µg/mL) prepared from the
stock solution of 1600µg/mL in RPMI 1640 medium was added
to wells in column one of plates containing fungal biofilms.
Then, the series of doubling dilutions of compound 4 were
created. Untreated biofilms containing RPMI 1640 and wells
containing medium without biofilm were included as positive
and negative controls, respectively. The plates were incubated
at 37◦C for 24 h without shaking. The antifungal effect was
monitored by using the metabolic 2,3-bis(2-metoxy-4-nitro-
5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT; Roche
Diagnostics GmbH) reduction assay, with optical density being
read at 490 nm (Bachmann et al., 2002; Pierce et al., 2010).
Eight replicate biofilms were included for each experiment, and
repeated on two separate occasions.
Statistical Analysis
Each experiment was performed at least three times, with
experimental values expressed as means ± SD. The statistical
differences between the control and test values were determined
by means of the Wilcoxon signed-rank matched-pair test.
Two-tailed P ≤ 0.05 were considered to be statistically
significant.
RESULTS
Antifungal Susceptibility Profile of Candida
spp. to Compound 4
In vitro susceptibility testing to compound 4 was performed
for 63 isolates. Percentage of growth inhibition was determined,
respectively, for 38 isolates at concentrations ranging from 16
to 0.5µg/mL (Table 2) and for 25 strains at 32–0.00195µg/mL
(Table 3). The proportion of strains that showed clear endpoint
was 22% (14 out of 63 strains) in the two experiments (Figure 2).
Compound 4 displayed a promising anti-Candida activity against
C. glabrata and C. tropicalis (100% of growth inhibition ranged
from 0.25 to 16µg/mL). Among 17 C. glabrata isolates that are
evaluated in the present study, 29% (5 out of 17) of strains
showed a clear endpoint. For C. tropicalis, 33% of the isolates
(3 out of 9 strains) were totally inhibited (clear endpoint).
Although, endpoint was visible mostly for the latter strains at
the range: 16–0.5µg/mL compared with the remaining strains
tested, it was evident that this effect appeared for C. krusei
after the extension of the concentration tested to 0.00195µg/mL
(0.25µg/mL = 100%). Unfortunately, compound 4 displayed
anti-Candida activity (without clear endpoint) against most of
the clinical strains ofC. albicans (76%).We observed the presence
of a visually assessed MIC in compound 4 with susceptibility
testing plates for 35% of strains (22 out of all 63 strains tested).
The proportion of strains that showed MIC was as follows:
14% (3 out of 22 strains) at concentrations: 0. 00195 and
0.0156µg/mL; 23% (5 out of 22) at 0.0039µg/mL; 27% (6 out
of 22 strains) at 0.0078µg/mL; as well as 4% (1 out of 22
strains) at concentrations: 0.0313–0.0625, 0.5–1, and 32µg/mL.
We found that the MIC values assessed visually corresponded to
a higher percentage of growth inhibition in wells (measurement
at OD405) compared to the remaining wells in a microdilution
assay (Table 3). We observed that under these conditions the
MIC value for one representative-reference strain of C. albicans
90028 was extremely high at 32µg/mL. The MIC value of
compound 4 against 90028 was significantly higher than that of
AmB (MICx128 of AmB). MIC range among most of the clinical
strains of C. albicans was 0.00195–0.0078µg/mL. Although, we
observed MIC only in 22 strains among the whole group tested,
this experiment was not affected by the compound precipitation
on well bottoms as compared to SCW.
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TABLE 2 | Antifungal activity (cells inhibition %; Means ± SD) of compound 4 against Candida clinical isolates after 48h.
Organism Origin Strain
designation
µ g/mL
16 8 4 2 1 0.5 0.625*
Candida
albicans(Ca)
Blood sample Ca no. 82 98.28± 0.17 98.44±0.42 99.03± 0.47 99.04± 0.58 99.02±0.29 99.10± 0.51 100
Ca no. 129 98.73± 0.77 98.65±0.76 98.68± 0.53 98.88± 0.19 98.91±0.06 99.03± 0.04 100
Ca no. 171 98.78± 0.14 98.74±0.01 98.95± 0.70 99.13± 0.10 99.01±0.20 98.92± 0.85 100
Drain swab Ca no. 87 99.13± 0.13 98.37±1.86 98.78± 0.35 99.31± 0.58 98.96±0.21 98.95± 0.98 100
Nose swab Ca no. 96 98.69± 0.83 99.06±0.11 99.02± 0.08 99.01± 0.16 99.00±0.09 99.11± 0.26 100
Ca no. 97 98.99± 0.06 98.94±0.13 99.03± 0.06 98.83± 0.17 98.98±0.05 98.94± 0.24 100
Sputum sample Ca no. 128 98.83± 0.04 98.90±0.29 98.64± 0.65 98.98± 0.36 98.91±0.46 98.85± 0.51 100
Vaginal swab Ca no. 16 98.97± 0.19 98.82±0.23 98.78± 0.32 98.98± 0.14 99.14±0.21 99.49± 0.62 100
Ca no. 28 98.20± 0.17 98.66±1.03 98.58± 1.07 99.25± 0.31 99.05±0.49 99.08± 0.26 100
Wound swab Ca no. 5 98.82± 0.11 98.89±0.21 98.88± 0.14 98.88± 0.14 98.91±0.13 98.86± 0.27 100
Ca no. 89 98.62± 0.17 98.77±0.24 99.01± 0.22 99.04± 0.30 98.78±0.31 99.10± 0.20 100
Candida
dubliniensis(Cd)
Reference Cd ATCC
MYA-581
99.88± 3.59 100±0.91 99.55± 0.87 98.76± 0.79 99.95±0.47 100± 2.08 100
Candida
glabrata (Cg)
Anus swab Cg no. 118 100± 3.92 100±0.74 100± 0.61 100± 2.57 99.18±1.45 99.76± 1.27 100
Drain swab Cg no. 4 99.05± 0.15 98.98±0.26 98.64± 0.47 98.78± 0.21 98.73±0.18 99.12± 0.18 100
Cg no. 40 100± 1.36 100±2.94 99.06± 1.92 98.88± 0.98 97.67±1.38 99.61± 0.54 100
Cg no. 70 99.17± 0.25 98.63±0.34 99.04± 0.27 99.16± 0.01 98.77±0.31 98.87± 0.26 100
Cg no. 88 98.47± 1.86 98.64±0.36 98.44± 0.51 98.51± 0.33 100±4.78 98.59± 1.59 100
Nose swab Cg no. 67 99.11± 0.32 98.34±0.35 98.87± 0.54 99.11± 0.35 98.98±0.48 99.16± 0.15 100
Cg no. 69 98.99± 0.18 98.97±0.46 98.91± 0.02 99.10± 0.26 98.99±0.33 99.00± 0.24 100
Oral cavity swab Cg no. 117 99.21± 1.20 97.92±5.45 95.11± 4.48 98.58± 0.92 98.44±0.06 98.53± 0.54 100
Stoma swab Cg no. 41 96.95± 1.44 98.80±1.01 99.43± 0.47 100± 4.17 100±1.01 100± 0.26 100
Wound swab Cg no. 73 98.83± 0.21 99.05±0.42 99.00± 0.36 98.85± 0.06 99.17±0.06 98.94± 0.26 100
Cg no. 75 99.05± 0.76 98.70±1.18 97.40± 5.36 98.56± 0.48 98.22±0.92 98.81± 0.58 100
Candida kefyr
(Ck)
Vaginal swab Ck no. 27 99.24± 0.32 98.61±0.85 99.30± 0.24 99.29± 0.93 98.62±0.91 98.82± 0.70 100
Candida
krusei (Ckr)
Bile sample Ckr no. 119 98.66± 0.23 98.47±0.68 99.23± 0.26 99.19± 0.04 98.98±0.29 99.09± 0.29 100
Candida
parapsilosis
(Cp)
Blood sample Cp no. 56 99.79± 1.06 99.39±5.11 97.46± 1.16 98.97± 0.51 98.70±0.46 100± 0.65 100
Cp no. 98 99.00± 0.17 99.10±0.24 98.94± 0.26 99.28± 0.11 98.82±1.03 99.00± 0.29 100
Central venous
catheter swab
Cp no. 55 98.85± 0.17 98.92±0.22 98.97± 0.34 99.06± 0.16 98.88±0.22 99.08± 0.20 100
Drain swab Cp no. 71 98.77± 1.07 98.98±0.09 98.94± 0.20 98.98± 0.17 98.91±0.17 98.83± 0.40 100
Oral cavity swab Cp no. 166 98.71± 0.23 99.11±0.24 98.90± 0.17 98.84± 0.09 98.94±0.09 98.96± 0.13 100
Ulcer swab Cp no. 120 98.85± 0.22 99.05±0.45 99.07± 0.43 99.05± 0.21 99.05±0.46 99.03± 0.32 100
Candida
tropicalis (Ct)
Blood sample Ct no. 53 83.13± 0.00 100±2.12 99.32± 1.77 99.78± 0.87 99.19±0.23 100± 0.66 100
Central venous
catheter swab
Ct no. 6 100± 0.00 100±0.00 100± 0.24 99.23± 0.88 97.76±9.04 98.27± 9.11 100
Drain swab Ct no. 68 98.98± 0.31 98.98±0.15 99.03± 0.21 99.09± 0.26 99.01±0.12 99.00± 0.16 100
Drain swab Ct no. 72 99.89± 0.03 99.70±0.64 93.67± 12.52 96.61± 11.35 98.97±0.55 98.91± 0.29 100
Sputum sample Ct no. 150 99.00± 0.04 99.07±0.49 98.94± 0.54 98.93± 0.19 99.03±0.07 98.94± 0.18 100
Urine sample Ct no. 168 98.94± 0.01 98.98±0.13 98.96± 0.30 99.03± 0.08 99.04±0.07 98.63± 1.42 100
Wound swab Ct no. 80 99.09± 0.23 98.99±0.24 99.14± 0.41 98.84± 0.16 98.87±0.13 99.01± 0.29 100
*stands for MIC of Amphotericin B (AmB) determined using the broth microdilution Method M27-A3, CISI, 2008, for AmB at the concentration of 0.625µg/mL against all strains tested
clear end point (100% growth reduction) was determined spectrophotometrically (optical density OD405).
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FIGURE 2 | Clear endpoint of the clinical strains of Candida spp. treated with compound 4 (β-ketosulfone) for 48h in the microdilution assay. Results
are expressed as percentages of total number of strains recorded for the antifungal susceptibility profile study. Assays were performed on 2 independent occasions
with 3 biological repeats (n = 3).
We examined if compound 4 was fungicidal against clinical
strains or if, contrariwise, it did not kill the cells and behaved
as a fungistatic agent against these strains. For this purpose after
growing the cells in compound 4 at concentrations from 32 to
2µg/mL, we passed them on YEPD agar plates (separately from
compound 4) and then assessed their antifungal susceptibility
to compound 4. We found that these concentrations have the
fungistatic effect on the following strains: Ca 90028, Ca 15, Cg
85, Ck 48, Cp 47, and Cp 43 (Table 4). As we showed, the effect
of compound 4 activity against the latter strains was stable within
this concentration range. Furthermore, compound 4 at 32µg/mL
exhibited fungicidal activity against nine strains tested (Table 4).
Compound 4 Paradoxical Effects among
Candida spp.
We found a typical paradoxical effect, defined as growth in
the presence of high concentrations of an antifungal agent
and the absence of growth at intermediate concentrations for
two clinical isolates tested: C. glabrata 144 and C. parapsilosis
46 (Table 4; Figure 3). We characterized this phenomenon in
detail, firstly the percentage of growth inhibition being evaluated
in the microdilution Method M27-A3, CISI, 2008 (Table 3).
Although, the MIC value for strain 144 was 0.0156µg/mL, we
did not observe a clear endpoint at the concentration ranging
from 32 to 0.00195µg/mL. Contrariwise, strain 46 reached MIC
at 0.0039µg/mL and clear endpoints were observed at 1 and
8µg/mL. These data indicated that paradoxical growth in the
presence of compound 4 is not frequent among the Candida
clinical isolates. We studied whether the growth characteristics
were dependent on compound 4 concentrations compared to
the control growth curves (Figure 3). The growth of control
cells fluctuated in line with the DMSO concentration and strain.
Compound 4 did not impair the final growth of yeast cells,
since the cells were able to reach the final OD at the highest
concentration (strain 144: 0.55 ± 0.004; strain 46: 0.35 ± 0.05)
after 48 h (Figures 3E,F). In line with this, compound 4 at
32µg/mL achieved only 3-log reduction of cells of both clinical
isolates in the MFC assay (Table 4). The latter phenomenon
was also noted for C. albicans 90028 (without paradoxical
effect, Figure 3A). In the case of C. albicans 14053, 2-log cell
reduction under compound 4 at the highest concentration tested
was observed (Table 4). No difference between the final OD at
32µg/mL (OD = 1.80 ± 0.02) and the growth control of strain
14053 (OD = 1.79 ± 0.009) was observed (Figure 3B). In line
with the latter, complete killing of 14053 was not observed at
the concentration of 32µg/mL in MFC assay. The remaining
references strains: C. albicans 28836 and C. krusei 6258 were
reduced for 10- and 9-log, respectively (Table 4; Figures 3C,D).
Effect of Compound 4 on C. albicans Cell
Wall
The MIC value of compound 4 against strain 90028, in medium
with sorbitol was seen at concentration of 266.5µg/mL. The same
effect was observed for compound 4 in medium without sorbitol.
Cells protected with sorbitol grew in the presence of compound
4 at concentrations ranging from 2.08 to 133.25µg/mL. The
findings showed that compound 4 does not interfere with cell wall
biosynthesis pathway because the susceptibility of yeast cells to it
was unaltered in the presence or absence of an osmotic protector
(Figure 4). The growth control ensured the viability of cells since
they were able to grow in the presence of sorbitol and the absence
of compound 4.
Compound 4 Displays Low Toxicity to Vero
Cells
Since Vero cells are the most common tool to assess
influence of chemical and other compounds on epithelial
cells (Ammerman et al., 2008), we employed them in our
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FIGURE 3 | Characterization of growth of Candida strains in the presence of compound 4. Optical densities at 405 nm were obtained after treatment with
different compound 4 concentrations. Control susceptibility test of compound 4 after 48 h against reference strains: C. albicans 90028 (A), C. albicans 14053 (B),
C. albicans 28836 (C), C. krusei 6258 (D). Susceptibility test against the clinical strains: C. parapsilosis 46 (E) and C. glabrata 144 (F). Testing antifungal susceptibility
to compound 4 was performed as described in Materials and Methods after 48 h. Test was performed in 3 independent experiments. Results are presented as
follows: *growth control in RPMI with DMSO dissolved in water (0.66% v/v); 1, 2, 3 stand for three independent susceptibility tests. (A) The 48-h incubation with
compound 4 yielded significantly reduced OD of 90028 at concentrations ranging from 16 to 32µg/mL. No paradoxical growth in the presence of agent in C. albicans
90028 was noted. (B) Optical densities obtained after 48 h of incubation of C. albicans 14053 indicated paradoxical effect. The graph showed significantly decreased
OD at 8µg/mL, which correspond to 9-log reduction of cfu of C. albicans 14053 (Table 4). (C) The curves of ODs of C. albicans 28836 plotted against compound 4
concentrations showed higher starting OD and a steeper decrease in the slope of the curve at 32µg/mL, which correspond to 10-log reduction (Table 4). (D) As
determined by optical density, dramatically reduced viability of cells of C. krusei 6258 after exposure to compound 4 relative to the control grown in the presence of
DMSO (0.66%) was seen. (E) C. parapsilosis 46 cells reduction after exposure to compound 4 correlated with end point at 8 and 1µg/mL (Table 3), and 4-log
reduction at concentrations ranging from 16 to 2µg/mL (Table 4). Paradoxical growth in C. krusei 46 was noted. (F) Growth of cells of C. glabrata 144 incubated in
the presence of 0.0156µg/mL of compound 4 was significantly reduced, which corresponded to MIC (Table 3) and elevated reduction of cell growth (ranging from 4-
to 10-log reduction at 8 and 16µg/mL, respectively, Table 4).
Frontiers in Microbiology | www.frontiersin.org 9 August 2016 | Volume 7 | Article 1309
Staniszewska et al. Novel β-Ketosulfone against Candida
TABLE 4 | Fungicidal activity of β-ketosulfone.
Strain designation Candida colony forming unites (cfu x104)
after treatment with β-ketosulfone (µg/Ml)
Control Candida colony
forming unites (cfu × 109)
Logarithm reduction of Candida unites after
β-ketosulfone 48-h influence
32 16 8 4 2 Untreated starting inoculum 32 16 8 4 2
C. a. 90028 ATCC 125 147 111 128 216 36 3-log 3-log 3-log 3-log 3-log
C.a. 14053 ATCC 59 129 0 124 158 0.9 2-log* 1-log* 9-log* 1-log* 1-log*
C.a. 28836 ATCC 0 16 63 71 123 2 10-log 3-log 3-log 1-log 2-log
C. a. 131 0 0 128 24 96 2 10-log 10-log 2-log 2-log 2-log
C.a. 15 198 85 125 97 69 2 1-log 2-log 2-log 2-log 2-log
C.a. 86 0 228 335 715 226 1 10-log 1-log 1-log 1-log 1-log
C.g. 144 3 0 13 3 0 3 3-log* 10-log* 4-log* 3-log* 10-log*
C.g. 44 0 18 33 36 58 7 10-log 4-log 4-log 3-log 4-log
C.g. 85 294 276 315 295 294 2 2-log 2-log 2-log 2-log 2-log
C.g. 92 0 0 0 0 0 1 10-log 10-log 10-log 10-log 10-log
C.k. 6258 ATCC 0 0 6 2 25 0.2 9-log 9-log 2-log 3-log 1-log
C.k. 122 0 0 83 66 226 1 10-log 10-log 2-log 2-log 2-log
C.k. 48 237 148 162 82 104 0.017 <1-log <1-log <1-log <1-log <1-log
C.k. 39 6 0 0 48 35 1 4-log 10-log 10-log 3-log 3-log
C.p. 47 150 535 881 439 492 9 2-log 2-log 2-log 2-log 1-log
C.p. 43 145 197 97 146 146 2 2-log 2-log 2-log 2-log 2-log
C.p. 46 117 33 41 78 13 4 3-log* 4-log* 4-log* 4-log* 4-log*
C.t. 152 42 33 39 0 0 0.4 4-log 2-log 2-log 9-log 9-log
Logarithm Reduction of Candida spp. Colony Forming Unites under β-ketosulfone Influence.
*stands for paradoxical effect evaluated in MFC assay performed in n = 3, where logarithm reduction of the colony number of each strain was compared to the starting inoculum grown
in RPMI medium with 0.66% DMSO (dissolved in water v/v).
study to estimate the compound 4′ cytotoxicity. Compound
4 at the highest concentration tested (256µg/mL) exhibited
almost 50% inhibition of Vero cells viability (CC50) after 18-h
treatment (Figure 5). Cytotoxicity assays performed in 96-well
plate revealed >CC20 of compound 4 at 64 and 32µg/mL,
respectively (Figure 5). At the concentration of 16µg/mL,
compound 4 caused a reduction of 16.49% in cells viability.
Treatment considering DMSO (solvent) at 2.6% (Figure 5)
caused approximately 12.26% reduction in the Vero cells
viability.
Citotoxicity of Compound 4 against G. mellonella
In vivo cytotoxicity test indicated that almost all larvae survived
when inoculated with compound 4. Low level of larval death
occurred in the one set (per three tested for each concentration)
of compound 4 at 32µg/mL. The latter may have result from the
unavoidable handling of larvae in the initial stages of the assays.
The results are presented in Figure 6. We evaluated the toxicity
of DMSO (solvent of compound 4) usingG.mellonella. We found
that DMSOdoes not induce toxicity against larvae that contribute
to the lack of toxicity evident following compound 4 challenges
(Figure 6). The level of DMSO-injected and untouched insects
remained constant (100% survival). Compound 4 injected larvae
were not significantly different from those of DMSO-challenged
and untouched insects at all-time points analyzed (Figure 6).
We did not observe the dark color of larvae associated with
the pigment melanin, an immune response by the insect to
compound 4.
Antifungal Susceptibility of C. albicans
Biofilm to Compound 4
The results obtained by XTT assay at 24 h are summarized in
Figure 7. The effect of Compound 4 on formed C. albicans
biofilms was minimal. Compound 4 at concentration of
0.5µg/mL inhibited the metabolic activity of cells within
biofilms but insignificant reduction was noted (<50%). A
similar trend was observed for the range of concentrations
2–1 and 16–8µg/mL. Furthermore, XTT assay denoted clear
metabolic activity of sessile cells in the presence of compound
4 at concentrations above the MICPI (determined in broth
microdilution method). Mean differences between the test and
control assays (100% growth) were not statistically significant
(p > 0.05).
Influence of Compound 4 on C. albicans
Morphogenesis during Sessile Growth on
Caco-2 Monolayer
The effect of compound 4 at MIC = 16µg/mL on C. albicans
morphogenesis during the interaction with Caco-2 cells was
visually determined (Figure 8). Strain 90028 exhibited no defects
in hyphal growth on Caco-2 monolayer. Thus, compound 4
at 16µg/mL had minor or none effect on sessile C. albicans
filament growth. As control, we observed a significant hypha
inhibition under Amphotericin B at 1µg/mL after 18-h
treatment.
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FIGURE 4 | MIC values (µg/mL) of β-ketosulfone (compound 4) in the presence of sorbitol (0.8 M) against C. albicans 90028. The solutions of compound 4
were dissolved in water with 0.66% (v/v) addition of DMSO. The yeast cells suspension at final density of 0.9× 109 cfu/mL SDB medium with sorbitol at final
concentration of 0.8M and DMSO at 0.66% was used in the experiment. Additionally, to accurately determine MICs for 90028, compound 4 at the range of
concentrations: 2.08–1066 in SDB medium without sorbitol was used.
FIGURE 5 | Analysis of Vero cells viability after 18-h treatment with compound 4. Cells viability was analyzed in parallel with DMSO (diluent).
DISCUSSION
Here we synthesized and characterized compound 4, the first,
to our knowledge, β-ketosulfone exhibiting fungicidal activity.
In our study, novel compound 4 was shown to possess effective
antifungal activity (MFC = 32–2µg/mL) against the Candida
reference strains and clinical isolates. Considering the structure-
dependent effect, we propose that the presence of bromine and
chlorine moiety attached to C2 of phenyl ring in compound
4 may be the reason of its high antifungal activity (Bondaryk
et al., 2015). As we showed previously, these elements are
important for the interactions with fungal cells (Bondaryk et al.,
2015; Staniszewska et al., 2015a,b). Indeed, bromodichloro- and
dichloro-methyl substituents have a crucial role for reducing
morphogenesis and adhesion of C. albicans without enhanced
toxicity. We studied the antifungal activity of new compound 4
against a variety of clinical isolates, including Candida species
that are difficult to treat, such as C. glabrata, C. krusei,
C. parapsilosis, and C. tropicalis. All strains of Candida were
classified as susceptible to new compound 4. Since, nearly 20%
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FIGURE 6 | Cytotoxicity of compound 4 against Galleria mellonella. Ten larvae were injected with compound 4 or DMSO (solvent used as a control) and
incubated at 37◦C for 72 h. The time of death of larvae was recorded after 18, 48, and 72 h of the post-treatment. Untouched larvae were used as a control of
injection stress. Results are the mean of three separate experiments, ± standard deviation.
FIGURE 7 | The XTT Assay Results of the C. albicans 90028 Biofilm
Susceptibility to Compound 4 At each concentration of compound 4,
the metabolic activity of biofilm was compared with the control biofilm
of 90028 (p > 0.05).
of C. glabrata strains exhibit intrinsic resistance to azoles and
its resistance to echinocandins is on the rise (with >10% of
isolates showing resistance; Shor and Perlin, 2015), we showed
that compound 4 can be an alternative against these multi-drug
resistant strains. A high mortality rate, in patients infected with
C. glabrata (80%) or C. tropicalis (77%; Bonfietti et al., 2012),
indicates the need to search for new, effective antifungals against
candidiasis. We found an epidemiological relationship between
the cases affected by Candida isolates and the sensitivity to
compound 4 (Tables 2, 3).
As PG is more common among Candida strains and stems
from compensatory responses to the inhibition of glucan
synthesis, our data strongly imply that compound 4 is unlikely
impact this effect in clinical strains. PG was evident exclusively
for only one clinical isolate, respectively, from species of
C. glabrata and C. parapsilosis and reference strain 14053 (3
out of 63 strains). This is not in line with previous studies
(Chamilos et al., 2007), where PG was described mainly for
C. krusei and C. tropicalis. To our knowledge, Shields et al. (2011)
reported paradoxical growth of C. glabrata. Despite findings
of Chamilos et al. (2007), it ought to be indicated that it is
species-related. PG has been demonstrated previously by other
authors (Bizerra et al., 2011; Shields et al., 2011; Rueda et al.,
2014) using a broth microdilution assay for detecting MIC
and MFC mainly for echinocandins. In our study, the MFC
assay was helpful in identifying PG of clinical isolates in the
presence of concentrations that exceeded MICs of compound
4 (2–16µg/mL), especially for C. glabrata and C. parapsilosis.
In fact, the MFC assay revealed PG that was not evident by
broth microdilution. To our knowledge, this is the first study to
demonstrate that compound 4 was associated with its own PG
when it was tested in the presence of concentration ranging from
2 to 16µg/mL. Our findings were consistent with earlier reports
suggested that this effect represents generalized compensatory
responses to a range of cell wall insults, rather than specific
responses to glucan synthesis. We showed that the MIC values of
compound 4 were unaltered in the presence of osmotic protector
(sorbitol), suggesting compound 4 does not act by inhibiting
fungal cell wall synthesis.
In the study, a biphasic killing of C. albicans biofilms was
observed, with the small population being killed at relatively
low compound 4 concentrations, and abundant fraction of cells
(persistent cells), remaining resistant at high concentration of
agent. Moreover, structural analyses revealed that compound 4-
treated biofilms showed minor defects in the biofilm architecture
(Figure 7). In our opinion, the reintroduction of fluorine atom
instead of chlorine at the C4 position of the benzene ring
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FIGURE 8 | Sessile Growth of C. albicans 90028 on slides with Caco-2 monolayer in 24-well plate. (A) Hyphal cells not treated with antifungals (arrow)
grown on cell line stained with acridine orange (arrowhead). (B) Conglomerate of hyphal forms (open arrow). (C) Under influence of Amphotericin B at 1µg/mL for
18 h, budding blastoconidial cells were seen (open arrow) with lack of true hyphae. (D) After 18-h influence of compound 4 at 16µg/mL, hyphal forms were observed
(arrow).
can exert activity against Candida sessile cells (Bondaryk et al.,
2015; Staniszewska et al., 2015a,b). Candida albicans biofilm
heterogeneity has a direct impact on antifungal sensitivity to
compound 4, based on our in vitro study. Our data illustrate
significant differences between planktonic and sessile cells of
C. albicans.While amphotericin B is equally effective against both
growing forms, compound 4 was less effective against mature
biofilms. Furthermore, we found a PG of lower percentage
metabolic reduction with higher concentration of compound 4
than with 0.5µg/mL in vitro (Figure 7). The exact mechanism
causing this PG with Candida strains and its clinical relevance
are unknown.
Following validation of antifungal activity, compound 4 was
finally checked for its toxicity, in order to provide evidence for
future clinical use. Overall, no cytotoxic activity was detected
against mammalian cells in vitro as well as G. mellonella
in vivo.
Finally, our findings with compound 4 suggest a general
strategy for antifungal agent development that might be useful
in limiting the emergence of resistance in Candida strains. As
caspofungin and amphotericin B exerted selective pressure on
C. glabrata, compound 4 can be alternative in patients at risk for
bloodstream infection. Characterization of various phenotypes of
clinical strains in the presence of compound 4 would indicate
that this antifungal agent is likely to impact the treatment of
patients with candidiasis. Our findings support the view that
β-ketosulfone warrant further explanation of their biological
properties and toxicity in non-clinical studies and clinical
trials.
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